Skip to main content
. 2017 Jun 8;135(6):586–593. doi: 10.1001/jamaophthalmol.2017.0988

Table 2. Cases of Prevalent Severe DR and Incident Cardiovascular Outcomes Included in This Meta-analysis.

DR Type or Outcome Study, Participants, No. (%)
ARIC AusDiab BDES BMES CHS LALES MESA WESDR
Type
DME 9 (0.5) 11 (1.3) 13 (2.9) 12 (4.3) 6 (1.5) 119 (9.6) 48 (6.1) 136 (7.6)
PDR 313 (17.0) 7 (0.9) 14 (3.1) 4 (3.1) 8 (2.0) NA 8 (1.0) 115 (6.5)
VTDR 321 (17.4) 14 (1.7) 24 (5.4) 15 (5.3) 10 (2.5) 119 (9.6) 50 (6.3) 198 (11.2)
Outcome
First CVD 379 (20.6) 63 (7.7) 147 (33.0) 62 (22.1) 133 (33.8) 87 (4.7) 37 (4.6) 295 (16.6)
Fatal CVD 29 (1.6) 31 (3.8) 82 (18.4) 49 (17.4) 90 (22.2) NA 5 (0.6) NA
First CHD 287 (15.6) 55 (6.7) 125 (28.0) 48 (17.1) 99 (24.4) 59 (4.8) 33 (4.2) 210 (11.8)
Fatal CHD 29 (1.6) 25 (3.1) 70 (15.7) 39 (13.9) 75 (18.5) NA 4 (0.5) NA

Abbreviations: ARIC, Atherosclerosis Risk in Communities; AusDiab, Australian Diabetes, Obesity, and Lifestyle Study; BDES, Beaver Dam Eye Study; BMES, Blue Mountains Eye Study; CHD, coronary heart disease; CHS, Cardiovascular Health Study; CVD, cardiovascular disease; DME, diabetic macular edema; DR, diabetic retinopathy; LALES, Los Angeles Latino Eye Study; MESA, Multi-Ethnic Study of Atherosclerosis Study; NA, not applicable; PDR, proliferative diabetic retinopathy; VTDR, vision-threatening diabetic retinopathy; WESDR, Wisconsin Epidemiologic Study of Diabetic Retinopathy.